Takeda Q2 FY2025 slides: Revenue hit by generics, pipeline and partnerships offer growth path
NeutralFinancial Markets

Takeda's Q2 FY2025 report reveals a decline in revenue due to the impact of generics, but the company is optimistic about future growth driven by its pipeline and strategic partnerships. This is significant as it highlights the challenges faced by pharmaceutical companies in maintaining revenue amidst increasing competition from generic drugs, while also showcasing Takeda's proactive approach to innovation and collaboration.
— Curated by the World Pulse Now AI Editorial System









